PMID- 23135865
OWN - NLM
STAT- MEDLINE
DCOM- 20130726
LR  - 20221207
IS  - 1437-7799 (Electronic)
IS  - 1342-1751 (Linking)
VI  - 17
IP  - 1
DP  - 2013 Feb
TI  - New strategy for the treatment of type 2 diabetes mellitus with incretin-based 
      therapy.
PG  - 10-5
LID - 10.1007/s10157-012-0709-0 [doi]
AB  - Incretin-based therapy was first made available for the treatment of type 2 
      diabetes mellitus (T2DM) in the US in 2006 and in Japan in 2009. Four DPP-4 
      inhibitors and two GLP-1 analog/receptor agonists are currently available. The 
      effects of incretin-based therapy are assumed to be exerted mainly through the 
      hormonal and neuronal actions of one of the incretins, GLP-1, which is secreted 
      from L cells localized in the small intestine. The benefits of this therapy over 
      conventional sulfonylureas or insulin injections, such as fewer hypoglycemic 
      events and reduced body weight gain, derive from the glucose-dependent 
      insulinotropic effect. The protective effects of this therapy on vulnerable 
      pancreatic beta-cells and against micro/macroangiopathy in T2DM are also most 
      welcome. Indications and/or contraindications for incretin-based therapy should 
      be clarified by prospectively studying the experiences of Japanese T2DM patients 
      undergoing this therapy in the clinical setting.
FAU - Namba, Mitsuyoshi
AU  - Namba M
AD  - Division of Diabetes and Metabolism, Department of Internal Medicine, Hyogo 
      College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo 663-8501, Japan. 
      namba-m@hyo-med.ac.jp
FAU - Katsuno, Tomoyuki
AU  - Katsuno T
FAU - Kusunoki, Yoshiki
AU  - Kusunoki Y
FAU - Matsuo, Toshihiro
AU  - Matsuo T
FAU - Miuchi, Masayuki
AU  - Miuchi M
FAU - Miyagawa, Jun-ichiro
AU  - Miyagawa J
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20121108
PL  - Japan
TA  - Clin Exp Nephrol
JT  - Clinical and experimental nephrology
JID - 9709923
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (GLP1R protein, human)
RN  - 0 (Glucagon-Like Peptide-1 Receptor)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Incretins)
RN  - 0 (Receptors, Glucagon)
RN  - 89750-14-1 (Glucagon-Like Peptide 1)
RN  - EC 3.4.14.5 (DPP4 protein, human)
RN  - EC 3.4.14.5 (Dipeptidyl Peptidase 4)
SB  - IM
MH  - Asian People
MH  - Diabetes Mellitus, Type 2/blood/diagnosis/*drug therapy/ethnology/physiopathology
MH  - Dipeptidyl Peptidase 4/metabolism
MH  - Dipeptidyl-Peptidase IV Inhibitors/therapeutic use
MH  - Glucagon-Like Peptide 1/analogs & derivatives/therapeutic use
MH  - Glucagon-Like Peptide-1 Receptor
MH  - Humans
MH  - Hypoglycemic Agents/adverse effects/*therapeutic use
MH  - Incretins/adverse effects/*therapeutic use
MH  - Insulin-Secreting Cells/drug effects/metabolism
MH  - Japan/epidemiology
MH  - Receptors, Glucagon/agonists/metabolism
MH  - Treatment Outcome
EDAT- 2012/11/09 06:00
MHDA- 2013/07/28 06:00
CRDT- 2012/11/09 06:00
PHST- 2012/05/23 00:00 [received]
PHST- 2012/10/01 00:00 [accepted]
PHST- 2012/11/09 06:00 [entrez]
PHST- 2012/11/09 06:00 [pubmed]
PHST- 2013/07/28 06:00 [medline]
AID - 10.1007/s10157-012-0709-0 [doi]
PST - ppublish
SO  - Clin Exp Nephrol. 2013 Feb;17(1):10-5. doi: 10.1007/s10157-012-0709-0. Epub 2012 
      Nov 8.